This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
miLab Platform Products
Improve diagnostic workflows
Improve diagnostic workflows
and accessibility at once
Beyond Diagnostics
We provide products and services that impact
We provide products and services that impact
one billion people's life in the world.
Noul focuses on the most challenging healthcare issues the world has yet to resolve.
We deliver innovative diagnostic solutions in blood and tissue diagnostics dramatically improve medical access and
conquer cancer.
-
Our Story in Numbers
- NVIDIA GTC selected AI Startups
- Top 0
- Cumulative investment (USD)
- 0million
- Annual sales growth (as of 2023)
- 0%
We continues to grow, moving toward the next stage.
-
- Patent registrations and applications
- 0cases, 0cases
- Cumulative orders for National R&D project (USD)
- 0million
- Researcher in company
- 0%
We creates innovation based on R&D and technology patents.
-
- Countries using miLab™
- 0countries
- Cumulative diagnosis using miLab™
- 0diagnoses
- Partner organizations
- 0+
miLab™ Solution leads the global blood and cancer diagnosis.
-
- Digitalize entire process (stain, scan, AI analyze)
- All inOne
- Time required for diagnosis (more than 2x improvement)
- Avg0mins
- Accuracy of test results (Based on miLab™ MAL)
-
Sensitivity0% ,
Specificity0%
miLab™ Solution has dramatically improved the diagnostic process.
Noul Highlights
Find our latest news
View More-
[Press Release] Noul Demonstrates ‘Expert-Level’ AI Diagnostic Performance in Europe… Results from Spain’s Carlos III Health Institute
Study of 329 Patients in Europe Shows Superior Performance Compared to Microscopic Diagnosis Sensitivity: 94.4%, Specificity: 97.2%, Agreement Rate: 92% September 24, 2024 – Noul Co., Ltd. (CEO: David Lim, hereafter referred to as “Noul”) has proven the expert-level diagnostic performance of its AI in Europe. Noul presented the AI… Read More
News | 2024.09.24
-
Noul Sustainability Report 2023-2024
In accordance with our Articles of Incorporation, Noul Co., Ltd. publishes sustainability reports to periodically review and disclose our corporate activities and achievements from economic, social, and environmental perspectives to our stakeholders. Through the annual publication of these sustainability reports, we aim to identify our ESG performance and areas… Read More
News | 2024.06.28
-
[Press Release] Noul Participates in a Malaria Project Initiated by U.S. CDC with Kenya Medical Research Institute
Gain attention as an alternative technology to the malaria HRP-2/3 gene deletion problem in Africa Prepare a bridgehead to enter the U.S. market by securing a credible reference June 17, 2024 – On-Device AI healthcare company, Noul, announced that it will jointly participate in a malaria diagnosis project initiated by… Read More
News | 2024.06.17
-
[Press Release] On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference
miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1% African authority on malaria diagnosis said “miLab is a potential game changer in accelerating access to parasitological confirmation” (Yongin, Korea) April 25, 2024 – Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced… Read More
Event | 2024.04.25
-
Noul, a top On-Device AI healthcare company, joins CancerX, a cancer-fighting project led by the U.S. White House
As part of the Cancer Moonshot initiative announced at the White House, noul is delighted to announce its groundbreaking participation as a leading On-Device AI healthcare company in the private-public partnership, CancerX. Congratulations on noul’s efforts to take a step closer to global cancer conquest! CancerX… Read More
News | 2024.02.26
-
[Press Release] On-Device AI Healthcare Company Noul Becomes an Official Member of Swiss Malaria GroupOn-Device AI Healthcare Company Noul
Obtain a membership in recognition of innovation in malaria diagnostic solution Strengthen global leadership in malaria diagnosis based on European subsidiary (Yongin, Korea) February 9, 2023 – Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that its European subsidiary (noul GmbH) has become an official member of… Read More
News | 2024.02.09
-
Career
Join our team, committed to
making a positive impact - View More
-
Sustainability at Noul
Sustainability is
at the core of our business philosophy. - Sustainability
